Brokerages Set Cutera, Inc. (NASDAQ:CUTR) PT at $45.00

Share on StockTwits

Cutera, Inc. (NASDAQ:CUTR) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $45.00.

CUTR has been the topic of a number of recent research reports. BidaskClub upgraded Cutera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 5th. ValuEngine lowered shares of Cutera from a “buy” rating to a “hold” rating in a research report on Tuesday. Maxim Group restated a “hold” rating on shares of Cutera in a research note on Friday, August 9th. Stephens lifted their price objective on shares of Cutera from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Finally, Zacks Investment Research downgraded shares of Cutera from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th.

Cutera stock traded up $0.38 during trading hours on Wednesday, hitting $37.47. 152,483 shares of the stock traded hands, compared to its average volume of 171,898. The firm’s 50 day moving average price is $34.30 and its 200-day moving average price is $27.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.66 and a quick ratio of 1.05. The stock has a market capitalization of $533.31 million, a price-to-earnings ratio of -16.80 and a beta of 0.96. Cutera has a 1 year low of $12.32 and a 1 year high of $39.15.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Thursday, November 7th. The medical device company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.23. Cutera had a negative return on equity of 84.67% and a negative net margin of 20.84%. The firm had revenue of $46.12 million during the quarter, compared to analysts’ expectations of $41.66 million. During the same period last year, the business posted $0.11 earnings per share. The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. Research analysts forecast that Cutera will post -0.71 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC purchased a new position in shares of Cutera during the 2nd quarter valued at about $31,000. First Quadrant L P CA purchased a new stake in shares of Cutera in the third quarter worth about $51,000. Quantamental Technologies LLC purchased a new stake in shares of Cutera in the second quarter worth about $37,000. JPMorgan Chase & Co. boosted its stake in shares of Cutera by 14.6% in the second quarter. JPMorgan Chase & Co. now owns 3,798 shares of the medical device company’s stock worth $76,000 after buying an additional 483 shares during the last quarter. Finally, Eqis Capital Management Inc. acquired a new stake in Cutera during the third quarter worth about $278,000. 91.46% of the stock is currently owned by institutional investors.

Cutera Company Profile

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

See Also: Using other technical indicators with support levels

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Lowers Anaplan  to Hold
Zacks Investment Research Lowers Anaplan to Hold
Zacks Investment Research Downgrades Arcus Biosciences  to Hold
Zacks Investment Research Downgrades Arcus Biosciences to Hold
Citigroup Boosts Signet Jewelers  Price Target to $22.00
Citigroup Boosts Signet Jewelers Price Target to $22.00
Ryerson  Rating Lowered to Strong Sell at ValuEngine
Ryerson Rating Lowered to Strong Sell at ValuEngine
Argus Reaffirms “Buy” Rating for Sun Life Financial
Argus Reaffirms “Buy” Rating for Sun Life Financial
S&P Global  Cut to “Market Perform” at Raymond James
S&P Global Cut to “Market Perform” at Raymond James


 
© 2006-2020 Zolmax.